Integra Lifesciences Stock Price, News & Analysis (NASDAQ:IART)

$54.07 +1.14 (+2.15 %)
(As of 02/25/2018 12:38 PM ET)
Previous Close$54.07
Today's Range$53.00 - $54.16
52-Week Range$40.51 - $56.42
Volume586,904 shs
Average Volume457,291 shs
Market Capitalization$4.24 billion
P/E Ratio88.64
Dividend YieldN/A
Beta0.67

About Integra Lifesciences (NASDAQ:IART)

Integra Lifesciences logoIntegra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions. It sells products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care. It also sells regenerative technology products for treating acute wounds, such as burns, and chronic wounds, including diabetic foot ulcers and surgical tissue repair. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery.

Receive IART News and Ratings via Email

Sign-up to receive the latest news and ratings for IART and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:IART
CUSIP45798520
Phone609-275-0500

Debt

Debt-to-Equity Ratio1.26%
Current Ratio4.49%
Quick Ratio3.39%

Price-To-Earnings

Trailing P/E Ratio88.6393442622951
Forward P/E Ratio29.07
P/E Growth1.72

Sales & Book Value

Annual Sales$992.08 million
Price / Sales4.28
Cash Flow$2.81 per share
Price / Cash19.21
Book Value$11.23 per share
Price / Book4.81

Profitability

Trailing EPS$0.61
Net Income$74.56 million
Net Margins4.52%
Return on Equity16.35%
Return on Assets6.83%

Miscellaneous

Employees3,700
Outstanding Shares78,480,000

Integra Lifesciences (NASDAQ:IART) Frequently Asked Questions

What is Integra Lifesciences' stock symbol?

Integra Lifesciences trades on the NASDAQ under the ticker symbol "IART."

When did Integra Lifesciences' stock split? How did Integra Lifesciences' stock split work?

Integra Lifesciences's stock split on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly issued shares were distributed to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of Integra Lifesciences stock prior to the split would have 200 shares after the split.

How were Integra Lifesciences' earnings last quarter?

Integra Lifesciences Holdings Corp (NASDAQ:IART) announced its quarterly earnings data on Thursday, October, 26th. The life sciences company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.47 by $0.02. The life sciences company had revenue of $278.83 million for the quarter, compared to analysts' expectations of $286 million. Integra Lifesciences had a net margin of 4.52% and a return on equity of 16.35%. The firm's revenue was up 11.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.93 earnings per share. View Integra Lifesciences' Earnings History.

When will Integra Lifesciences make its next earnings announcement?

Integra Lifesciences is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Integra Lifesciences.

Where is Integra Lifesciences' stock going? Where will Integra Lifesciences' stock price be in 2018?

10 brokerages have issued 12-month price objectives for Integra Lifesciences' shares. Their forecasts range from $44.00 to $58.00. On average, they expect Integra Lifesciences' share price to reach $51.88 in the next twelve months. View Analyst Ratings for Integra Lifesciences.

What are Wall Street analysts saying about Integra Lifesciences stock?

Here are some recent quotes from research analysts about Integra Lifesciences stock:

  • 1. Cantor Fitzgerald analysts commented, "IART announced preliminary 4Q revenue of $365MM, beating FactSet consensus by $13MM. The beat was driven by better than expected contribution from the Codman and DermaScience acquisitions." (1/5/2018)
  • 2. According to Zacks Investment Research, "Integra LifeSciences' contracting adjusted operating margin and adjusted gross margin have been causing troubles for the company of late. Also the company’s decision to sell its certain neurosurgery assets to Natus Medical may hamper its business in near term. However, the strong year-over-year increase in revenues on the back of strong growth within Orthopedics and Tissue Technologies segment buoys optimism. Raised full-year revenue guidance is indicative of this bullish trend to remain. We are happy with the fact that, the company is efficiently executing its growth plan through an efficient management team. However, the slashed full-year adjusted earnings range remains a concern. Overall, over the past year, Integra Lifesciences has been trading above the broader industry." (12/26/2017)

Who are some of Integra Lifesciences' key competitors?

Who are Integra Lifesciences' key executives?

Integra Lifesciences' management team includes the folowing people:

  • Stuart M. Essig Ph.D., Independent Chairman of the Board
  • Peter J. Arduini, President, Chief Executive Officer, Director
  • Glenn G. Coleman, Chief Financial Officer, Corporate Vice President
  • Lisa Evoli, Corporate Vice President, Chief Human Resources Officer
  • Jeffrey Mosebrook, Principal Accounting Officer, Vice President, Corporate Controller
  • Kenneth Burhop Ph.D., Chief Scientific Officer, Corporate Vice President
  • John Mooradian, Corporate Vice President - Global Operations and Supply Chain
  • Richard D. Gorelick, Corporate Vice President, General Counsel, Administration, Secretary
  • Robert T. Davis Jr., Corporate Vice President, President — Specialty Surgical Solutions
  • Judith E. O'Grady R.N., Corporate Vice President - Global Regulatory Affairs

Who owns Integra Lifesciences stock?

Integra Lifesciences' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.37%), Champlain Investment Partners LLC (5.92%), Clearbridge Investments LLC (1.65%), Glenmede Trust Co. NA (1.39%), Goldman Sachs Group Inc. (1.35%) and Jennison Associates LLC (1.29%). Company insiders that own Integra Lifesciences stock include Barbara B Hill, Christian S Schade, Daniel L Reuvers, Donald E Morel Jr, Glenn Coleman, James M Sullivan, Jeffrey Mosebrook, Joseph Vinhais, Peter J Arduini, Raymond G Murphy, Richard D Gorelick and Stuart Essig. View Institutional Ownership Trends for Integra Lifesciences.

Who sold Integra Lifesciences stock? Who is selling Integra Lifesciences stock?

Integra Lifesciences' stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Vaughan Nelson Investment Management L.P., OppenheimerFunds Inc., Allianz Asset Management GmbH, Eaton Vance Management, Goldman Sachs Group Inc., Pier Capital LLC and Chartwell Investment Partners LLC. Company insiders that have sold Integra Lifesciences company stock in the last year include Glenn Coleman, James M Sullivan, Jeffrey Mosebrook, Richard D Gorelick and Stuart Essig. View Insider Buying and Selling for Integra Lifesciences.

Who bought Integra Lifesciences stock? Who is buying Integra Lifesciences stock?

Integra Lifesciences' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Broadfin Capital LLC, Renaissance Technologies LLC, Champlain Investment Partners LLC, Arizona State Retirement System, Gotham Asset Management LLC, Wells Fargo & Company MN and Engineers Gate Manager LP. Company insiders that have bought Integra Lifesciences stock in the last two years include Barbara B Hill and Donald E Morel Jr. View Insider Buying and Selling for Integra Lifesciences.

How do I buy Integra Lifesciences stock?

Shares of Integra Lifesciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Integra Lifesciences' stock price today?

One share of Integra Lifesciences stock can currently be purchased for approximately $54.07.

How big of a company is Integra Lifesciences?

Integra Lifesciences has a market capitalization of $4.24 billion and generates $992.08 million in revenue each year. The life sciences company earns $74.56 million in net income (profit) each year or $0.61 on an earnings per share basis. Integra Lifesciences employs 3,700 workers across the globe.

How can I contact Integra Lifesciences?

Integra Lifesciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at 609-275-0500 or via email at [email protected]


MarketBeat Community Rating for Integra Lifesciences (IART)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  284 (Vote Outperform)
Underperform Votes:  295 (Vote Underperform)
Total Votes:  579
MarketBeat's community ratings are surveys of what our community members think about Integra Lifesciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Integra Lifesciences (NASDAQ:IART) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.302.302.602.80
Ratings Breakdown: 0 Sell Rating(s)
7 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $51.88$51.88$53.33$52.35
Price Target Upside: 5.50% upside5.50% upside9.33% upside4.47% upside

Integra Lifesciences (NASDAQ:IART) Consensus Price Target History

Price Target History for Integra Lifesciences (NASDAQ:IART)

Integra Lifesciences (NASDAQ:IART) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/11/2018OppenheimerReiterated RatingBuyMediumView Rating Details
1/9/2018BarclaysReiterated RatingHold$53.00LowView Rating Details
1/5/2018Cantor FitzgeraldReiterated RatingNeutral -> Neutral$52.00MediumView Rating Details
1/2/2018Raymond James FinancialReiterated RatingOutperform -> Market Perform$55.00MediumView Rating Details
1/2/2018Bank of AmericaDowngradeBuy -> NeutralHighView Rating Details
11/9/2017Royal Bank of CanadaReiterated RatingSector Perform -> Sector Perform$48.00 -> $50.00N/AView Rating Details
10/29/2017Wells Fargo & CoDowngradeOutperform -> Market PerformN/AView Rating Details
10/29/2017Jefferies GroupReiterated RatingBuy$56.00N/AView Rating Details
10/27/2017JPMorgan Chase & Co.DowngradeOverweight -> Neutral$44.00N/AView Rating Details
3/22/2017Piper Jaffray CompaniesReiterated RatingOverweight$47.00LowView Rating Details
1/6/2017JMP SecuritiesUpgradeMarket Perform -> Outperform$50.00N/AView Rating Details
10/28/2016Lake Street CapitalUpgradeHold -> Buy$46.00N/AView Rating Details
9/23/2016ArgusBoost Price TargetBuy$45.00 -> $52.50N/AView Rating Details
(Data available from 2/25/2016 forward)

Earnings

Integra Lifesciences (NASDAQ:IART) Earnings History and Estimates Chart

Earnings by Quarter for Integra Lifesciences (NASDAQ:IART)

Integra Lifesciences (NASDAQ IART) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018$0.56N/AView Earnings Details
10/26/2017Q3 2017$0.47$0.45$286.00 million$278.83 millionViewN/AView Earnings Details
7/26/2017Q2 2017$0.45$0.45$283.58 million$282.16 millionViewN/AView Earnings Details
4/26/2017Q1 17$0.40$0.39$254.19 million$258.60 millionViewN/AView Earnings Details
2/23/2017Q4 2016$0.52$0.52$257.27 million$255.70 millionViewN/AView Earnings Details
10/27/2016Q3$0.89$0.93$249.30 million$250.30 millionViewListenView Earnings Details
7/28/2016Q216$0.76$0.79$243.17 million$249.30 millionViewListenView Earnings Details
4/27/2016Q116$0.73$0.74$230.66 million$236.80 millionViewListenView Earnings Details
2/25/2016Q4$0.86$0.87$241.11 million$241.20 millionViewListenView Earnings Details
11/3/2015Q315$0.74$0.75$224.08 million$226.40 millionViewListenView Earnings Details
7/30/2015Q215$0.73$0.79$239.91 million$244.10 millionViewListenView Earnings Details
4/30/2015Q115$0.63$0.76$229.69 million$233.70 millionViewN/AView Earnings Details
2/24/2015Q414$0.89$0.94$244.39 million$252.20 millionViewListenView Earnings Details
11/3/2014Q314$0.74$0.76$233.50 million$229.70 millionViewListenView Earnings Details
8/5/2014Q214$0.63$0.68$229.32 million$231.40 millionViewN/AView Earnings Details
5/1/2014Q114$0.58$0.57$213.30 million$215.00 millionViewN/AView Earnings Details
2/25/2014Q413$0.81$0.78$223.37 million$220.80 millionViewN/AView Earnings Details
10/28/2013Q313$0.70$0.72$214.05 million$213.20 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.55$0.60$207.30 million$205.50 millionViewN/AView Earnings Details
5/2/2013Q1 2013$0.37$0.39$195.20 million$196.70 millionViewN/AView Earnings Details
2/21/2013Q4 2012$0.76$0.78$215.90 million$214.40 millionViewN/AView Earnings Details
10/24/2012$0.77$0.85ViewN/AView Earnings Details
7/26/2012$0.69$0.74ViewN/AView Earnings Details
4/25/2012$0.60$0.71ViewN/AView Earnings Details
2/23/2012$0.55$0.72ViewN/AView Earnings Details
10/31/2011$0.77$0.77ViewN/AView Earnings Details
7/28/2011$0.61$0.70ViewN/AView Earnings Details
4/28/2011$0.66$0.66ViewN/AView Earnings Details
2/24/2011$0.73$0.80ViewN/AView Earnings Details
10/28/2010Q3 2010$0.33$0.33ViewN/AView Earnings Details
7/29/2010Q2 2010$0.32$0.34ViewN/AView Earnings Details
5/3/2010Q1 2010$0.28$0.31ViewN/AView Earnings Details
3/1/2010Q4 2009$0.29$0.30ViewN/AView Earnings Details
11/4/2009Q3 2009$0.26$0.27ViewN/AView Earnings Details
8/6/2009Q2 2009$0.25$0.26ViewN/AView Earnings Details
5/6/2009Q1 2009$0.23$0.23ViewN/AView Earnings Details
3/2/2009Q4 2008$0.28$0.27ViewN/AView Earnings Details
11/7/2008Q3 2008$0.23$0.24ViewN/AView Earnings Details
8/11/2008Q2 2008$0.23$0.25ViewN/AView Earnings Details
6/4/2008Q1 2008$0.20$0.25ViewN/AView Earnings Details
5/17/2008Q4 2007$0.27ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Integra Lifesciences (NASDAQ:IART) Earnings Estimates

2018 EPS Consensus Estimate: $2.28
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.45$0.53$0.50
Q2 20183$0.54$0.56$0.55
Q3 20183$0.57$0.60$0.58
Q4 20183$0.62$0.70$0.65
Q1 20191$0.61$0.61$0.61
Q2 20191$0.62$0.62$0.62
Q3 20191$0.66$0.66$0.66
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Integra Lifesciences (NASDAQ:IART)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Integra Lifesciences (NASDAQ IART) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 21.50%
Institutional Ownership Percentage: 86.39%
Insider Trades by Quarter for Integra Lifesciences (NASDAQ:IART)
Institutional Ownership by Quarter for Integra Lifesciences (NASDAQ:IART)

Integra Lifesciences (NASDAQ IART) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/20/2017Jeffrey MosebrookInsiderSell160$47.41$7,585.60View SEC Filing  
11/14/2017Richard D GorelickVPSell1,500$47.19$70,785.0021,665View SEC Filing  
10/31/2017Barbara B HillDirectorBuy10,768$46.66$502,434.8855,540View SEC Filing  
8/4/2017Donald E Morel JrDirectorBuy10,000$49.25$492,500.0029,612View SEC Filing  
8/3/2017Donald E Morel JrDirectorBuy2,500$49.29$123,225.0029,612View SEC Filing  
8/1/2017Barbara B HillDirectorBuy5,050$49.33$249,116.5044,772View SEC Filing  
5/25/2017Stuart EssigDirectorSell135,000$49.90$6,736,500.002,077,475View SEC Filing  
5/23/2017Stuart EssigDirectorSell140,000$48.01$6,721,400.00View SEC Filing  
5/4/2017Glenn ColemanVPSell13,865$45.91$636,542.1518,519View SEC Filing  
5/4/2017James M SullivanDirectorSell15,658$45.89$718,545.6270,154View SEC Filing  
11/8/2016Peter J ArduiniCEOSell24,009$79.51$1,908,955.5925,593View SEC Filing  
8/23/2016Raymond G MurphyDirectorSell2,600$86.64$225,264.0033,047View SEC Filing  
8/9/2016Peter J ArduiniCEOSell24,009$84.52$2,029,240.6829,602View SEC Filing  
8/4/2016Raymond G MurphyDirectorSell2,610$84.83$221,406.3033,057View SEC Filing  
8/1/2016Richard D GorelickVPSell4,000$84.60$338,400.009,702View SEC Filing  
5/9/2016Joseph VinhaisVPSell972$73.36$71,305.924,311View SEC Filing  
5/4/2016Glenn ColemanCFOSell3,563$70.62$251,619.0612,263View SEC Filing  
5/3/2016Christian S SchadeDirectorSell7,829$70.42$551,318.1818,550View SEC Filing  
5/2/2016Daniel L ReuversVPSell1,000$71.43$71,430.009,747View SEC Filing  
4/29/2016Richard D GorelickVPSell4,000$70.72$282,880.0013,702View SEC Filing  
4/27/2016Stuart EssigDirectorSell104,390$70.15$7,322,958.501,064,709View SEC Filing  
4/6/2016Stuart EssigDirectorSell21,100$66.19$1,396,609.00981,419View SEC Filing  
4/5/2016Stuart EssigDirectorSell83,290$66.68$5,553,777.201,002,469View SEC Filing  
4/4/2016Stuart EssigDirectorSell42,150$67.26$2,835,009.001,002,469View SEC Filing  
5/7/2015Stuart EssigDirectorSell75,000$64.32$4,824,000.00View SEC Filing  
5/6/2015Stuart EssigDirectorSell125,000$64.83$8,103,750.00View SEC Filing  
1/2/2015Judith OgradyVPSell3,500$53.33$186,655.00View SEC Filing  
10/28/2014Stuart EssigDirectorSell147,098$49.58$7,293,118.84View SEC Filing  
10/27/2014Stuart EssigDirectorSell41,268$49.56$2,045,242.08View SEC Filing  
9/2/2014Judith OgradyVPSell2,500$49.82$124,550.00View SEC Filing  
8/27/2014Richard D GorelickVPSell7,000$50.03$350,210.00View SEC Filing  
8/25/2014John B Henneman IIICAOSell20,000$50.12$1,002,400.00View SEC Filing  
8/22/2014Deborah A LeonettiVPSell1,000$50.96$50,960.00View SEC Filing  
8/8/2014Brian LarkinVPSell1,947$48.28$94,001.16View SEC Filing  
7/30/2014Stuart EssigDirectorSell50,800$47.76$2,426,208.00View SEC Filing  
7/23/2014Stuart EssigDirectorSell27,819$47.80$1,329,748.20View SEC Filing  
7/1/2014Judith OgradyVPSell2,500$47.54$118,850.00View SEC Filing  
6/23/2014Stuart EssigDirectorSell21,381$47.76$1,021,156.56View SEC Filing  
4/3/2014Stuart EssigDirectorSell6,344$46.01$291,887.441,051,166View SEC Filing  
4/2/2014Stuart EssigDirectorSell76,177$46.05$3,507,950.851,057,510View SEC Filing  
3/31/2014Stuart EssigDirectorSell17,479$46.05$804,907.951,133,687View SEC Filing  
3/10/2014Deborah LeonettiVPSell7,563$49.22$372,250.869,955View SEC Filing  
3/4/2014Richard GorelickVPSell2,000$47.98$95,960.0018,296View SEC Filing  
2/28/2014Christian SchadeDirectorSell7,500$47.06$352,950.0011,902View SEC Filing  
2/27/2014Brian LarkinVPSell3,265$46.15$150,679.7510,256View SEC Filing  
2/27/2014John Henneman IIICFOSell5,000$46.07$230,350.0063,611View SEC Filing  
1/16/2014Stuart EssigDirectorSell8,037$49.59$398,554.831,151,166View SEC Filing  
1/14/2014Stuart EssigDirectorSell10,600$49.50$524,700.001,151,166View SEC Filing  
1/13/2014Stuart EssigDirectorSell99,032$49.51$4,903,074.321,151,166View SEC Filing  
1/9/2014Stuart EssigDirectorSell114,431$49.58$5,673,488.981,151,166View SEC Filing  
8/30/2013Richard GorelickVPSell3,000$40.79$122,370.0020,296View SEC Filing  
8/23/2013Deborah LeonettiVPSell8,906$41.68$371,202.0817,518View SEC Filing  
8/19/2013Brian LarkinVPSell7,490$41.90$313,831.0013,521View SEC Filing  
8/19/2013John Henneman IIICFOSell30,000$42.08$1,262,400.0072,669View SEC Filing  
8/1/2013Judith OgradyVPSell1,000$39.50$39,500.00View SEC Filing  
7/30/2013Judith OgradyVPSell2,000$38.50$77,000.00View SEC Filing  
5/31/2013Jerry E CorbinVPSell1,876$38.07$71,419.32View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Integra Lifesciences (NASDAQ IART) News Headlines

Source:
DateHeadline
Integra Lifesciences Holdings Corp (IART) Expected to Post Quarterly Sales of $364.94 MillionIntegra Lifesciences Holdings Corp (IART) Expected to Post Quarterly Sales of $364.94 Million
www.americanbankingnews.com - February 25 at 8:30 AM
Schwab Charles Investment Management Inc. Has $15.49 Million Stake in Integra Lifesciences Holdings Corp (IART)Schwab Charles Investment Management Inc. Has $15.49 Million Stake in Integra Lifesciences Holdings Corp (IART)
www.americanbankingnews.com - February 25 at 5:40 AM
Arizona State Retirement System Raises Stake in Integra Lifesciences Holdings Corp (IART)Arizona State Retirement System Raises Stake in Integra Lifesciences Holdings Corp (IART)
www.americanbankingnews.com - February 25 at 4:20 AM
Analyzing Cardiovascular Systems (CSII) & Integra Lifesciences (IART)Analyzing Cardiovascular Systems (CSII) & Integra Lifesciences (IART)
www.americanbankingnews.com - February 24 at 3:38 PM
Integra LifeSciences to Present at Healthcare Conferences in March 2018Integra LifeSciences to Present at Healthcare Conferences in March 2018
finance.yahoo.com - February 21 at 5:14 PM
Integra Lifesciences (IART) to Release Quarterly Earnings on TuesdayIntegra Lifesciences (IART) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 20 at 2:14 AM
Analyzing Align Technology (ALGN) & Integra Lifesciences (IART)Analyzing Align Technology (ALGN) & Integra Lifesciences (IART)
www.americanbankingnews.com - February 16 at 11:34 AM
Integra Lifesciences (IART) Upgraded at TheStreetIntegra Lifesciences (IART) Upgraded at TheStreet
www.americanbankingnews.com - February 10 at 2:28 PM
Zacks: Analysts Expect Integra Lifesciences Holdings Corp (IART) Will Post Quarterly Sales of $364.94 MillionZacks: Analysts Expect Integra Lifesciences Holdings Corp (IART) Will Post Quarterly Sales of $364.94 Million
www.americanbankingnews.com - February 8 at 9:04 AM
Integra LifeSciences Global Prospects Solid, Competition RifeIntegra LifeSciences Global Prospects Solid, Competition Rife
finance.yahoo.com - February 2 at 4:02 PM
Integra Lifesciences Holdings Corp (IART) Given Consensus Rating of "Hold" by BrokeragesIntegra Lifesciences Holdings Corp (IART) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 2 at 1:59 PM
Integra LifeSciences to Host Fourth Quarter 2017 Earnings Results Conference Call on February 27, 2018Integra LifeSciences to Host Fourth Quarter 2017 Earnings Results Conference Call on February 27, 2018
finance.yahoo.com - February 2 at 9:43 AM
Brokers Issue Forecasts for Integra Lifesciences Holdings Corps FY2017 Earnings (IART)Brokers Issue Forecasts for Integra Lifesciences Holdings Corp's FY2017 Earnings (IART)
www.americanbankingnews.com - January 30 at 6:44 AM
Contrasting Integra Lifesciences (IART) & T2 Biosystems (TTOO)Contrasting Integra Lifesciences (IART) & T2 Biosystems (TTOO)
www.americanbankingnews.com - January 10 at 3:28 PM
Integra Lifesciences Holdings Corp Forecasted to Post FY2017 Earnings of $1.84 Per Share (IART)Integra Lifesciences Holdings Corp Forecasted to Post FY2017 Earnings of $1.84 Per Share (IART)
www.americanbankingnews.com - January 10 at 6:56 AM
Integra Lifesciences (IART) "Hold" Rating Reiterated at BarclaysIntegra Lifesciences' (IART) "Hold" Rating Reiterated at Barclays
www.americanbankingnews.com - January 9 at 11:22 AM
Integra Lifesciences Holdings Corp (IART) Receives Average Rating of "Hold" from AnalystsIntegra Lifesciences Holdings Corp (IART) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 8 at 12:40 PM
Analyzing DENTSPLY SIRONA (XRAY) and Integra Lifesciences (IART)Analyzing DENTSPLY SIRONA (XRAY) and Integra Lifesciences (IART)
www.americanbankingnews.com - January 7 at 5:06 AM
Integra Lifesciences (IART) Neutral Rating Reaffirmed at Cantor FitzgeraldIntegra Lifesciences' (IART) Neutral Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - January 6 at 11:50 PM
Integra Lifesciences (IART) Downgraded to Strong Sell at BidaskClubIntegra Lifesciences (IART) Downgraded to Strong Sell at BidaskClub
www.americanbankingnews.com - January 6 at 11:08 AM
 Brokerages Expect Integra Lifesciences Holdings Corp (IART) Will Post Quarterly Sales of $351.57 Million Brokerages Expect Integra Lifesciences Holdings Corp (IART) Will Post Quarterly Sales of $351.57 Million
www.americanbankingnews.com - January 5 at 12:40 PM
Integra Lifesciences (IART) Market Perform Rating Reiterated at Raymond James FinancialIntegra Lifesciences' (IART) Market Perform Rating Reiterated at Raymond James Financial
www.americanbankingnews.com - January 2 at 11:04 AM
Integra LifeSciences Holdings Corp. breached its 50 day moving average in a Bearish Manner : IART-US : January 1, 2018Integra LifeSciences Holdings Corp. breached its 50 day moving average in a Bearish Manner : IART-US : January 1, 2018
finance.yahoo.com - January 1 at 11:09 AM
IART Makes Notable Cross Below Critical Moving AverageIART Makes Notable Cross Below Critical Moving Average
www.nasdaq.com - December 30 at 10:59 AM
Integra Lifesciences (IART) Rating Increased to Hold at Zacks Investment ResearchIntegra Lifesciences (IART) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - December 26 at 4:29 PM
Integra LifeSciences Holdings Corporation (IART) Expected to Announce Quarterly Sales of $351.58 MillionIntegra LifeSciences Holdings Corporation (IART) Expected to Announce Quarterly Sales of $351.58 Million
www.americanbankingnews.com - December 19 at 4:30 AM
$0.56 Earnings Per Share Expected for Integra LifeSciences Holdings Corporation (IART) This Quarter$0.56 Earnings Per Share Expected for Integra LifeSciences Holdings Corporation (IART) This Quarter
www.americanbankingnews.com - December 17 at 7:26 PM
Integra LifeSciences Holdings Corporation (IART) Given Average Rating of "Hold" by BrokeragesIntegra LifeSciences Holdings Corporation (IART) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - December 14 at 2:36 PM
Integra LifeSciences Holdings Corporation Forecasted to Earn Q3 2018 Earnings of $0.58 Per Share (IART)Integra LifeSciences Holdings Corporation Forecasted to Earn Q3 2018 Earnings of $0.58 Per Share (IART)
www.americanbankingnews.com - December 14 at 1:32 PM
Q1 2018 EPS Estimates for Integra LifeSciences Holdings Corporation (IART) Lifted by Jefferies GroupQ1 2018 EPS Estimates for Integra LifeSciences Holdings Corporation (IART) Lifted by Jefferies Group
www.americanbankingnews.com - December 13 at 10:26 AM
Zacks Investment Research Downgrades Integra LifeSciences (IART) to SellZacks Investment Research Downgrades Integra LifeSciences (IART) to Sell
www.americanbankingnews.com - December 13 at 10:20 AM
Oppenheimer Analysts Give Integra LifeSciences (IART) a $58.00 Price TargetOppenheimer Analysts Give Integra LifeSciences (IART) a $58.00 Price Target
www.americanbankingnews.com - December 12 at 10:04 AM
Integra LifeSciences Reaffirms Earnings View For FY17, FY18 - Quick FactsIntegra LifeSciences Reaffirms Earnings View For FY17, FY18 - Quick Facts
www.nasdaq.com - December 11 at 11:36 AM
Integra LifeSciences Hosts Investor Day 2017 New York CityIntegra LifeSciences Hosts Investor Day 2017 New York City
feeds.benzinga.com - December 11 at 8:03 AM
Integra LifeSciences Holdings Corp. – Value Analysis (NASDAQ:IART) : December 5, 2017Integra LifeSciences Holdings Corp. – Value Analysis (NASDAQ:IART) : December 5, 2017
finance.yahoo.com - December 5 at 3:33 PM
Integra LifeSciences Holdings Corp. breached its 50 day moving average in a Bullish Manner : IART-US : December 4, 2017Integra LifeSciences Holdings Corp. breached its 50 day moving average in a Bullish Manner : IART-US : December 4, 2017
finance.yahoo.com - December 4 at 11:12 AM
Integra (IART) Up 1.8% Since Earnings Report: Can It Continue?Integra (IART) Up 1.8% Since Earnings Report: Can It Continue?
finance.yahoo.com - November 27 at 5:27 PM
Integra LifeSciences Holdings Co. (IART) Receives Consensus Recommendation of "Buy" from AnalystsIntegra LifeSciences Holdings Co. (IART) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 19 at 11:54 AM
Analyzing VWR Corporation (VWR) & Integra LifeSciences Holdings (IART)Analyzing VWR Corporation (VWR) & Integra LifeSciences Holdings (IART)
www.americanbankingnews.com - November 19 at 9:40 AM
ETFs with exposure to Integra LifeSciences Holdings Corp. : November 16, 2017ETFs with exposure to Integra LifeSciences Holdings Corp. : November 16, 2017
finance.yahoo.com - November 17 at 5:22 AM
Insider Selling: Integra LifeSciences Holdings Corporation (IART) VP Sells 1,500 Shares of StockInsider Selling: Integra LifeSciences Holdings Corporation (IART) VP Sells 1,500 Shares of Stock
www.americanbankingnews.com - November 15 at 10:29 PM
Integra LifeSciences Holdings Corporation (IART) Expected to Announce Quarterly Sales of $361.17 MillionIntegra LifeSciences Holdings Corporation (IART) Expected to Announce Quarterly Sales of $361.17 Million
www.americanbankingnews.com - November 12 at 3:08 AM
Integra Gains on Global Growth, Hurricanes Hamper BusinessIntegra Gains on Global Growth, Hurricanes Hamper Business
finance.yahoo.com - November 3 at 8:24 AM
ETFs with exposure to Integra LifeSciences Holdings Corp. : November 2, 2017ETFs with exposure to Integra LifeSciences Holdings Corp. : November 2, 2017
finance.yahoo.com - November 3 at 8:24 AM
Integra LifeSciences Holdings Corp. :IART-US: Earnings Analysis: Q3, 2017 By the Numbers : November 1, 2017Integra LifeSciences Holdings Corp. :IART-US: Earnings Analysis: Q3, 2017 By the Numbers : November 1, 2017
finance.yahoo.com - November 2 at 1:32 AM
Insider Buying: Integra LifeSciences Holdings Corporation (IART) Director Purchases 10,768 Shares of StockInsider Buying: Integra LifeSciences Holdings Corporation (IART) Director Purchases 10,768 Shares of Stock
www.americanbankingnews.com - November 1 at 5:44 PM
Integra LifeSciences Holdings Corporation (IART) Forecasted to Earn FY2017 Earnings of $1.86 Per ShareIntegra LifeSciences Holdings Corporation (IART) Forecasted to Earn FY2017 Earnings of $1.86 Per Share
www.americanbankingnews.com - November 1 at 9:38 AM
Northcoast Research Weighs in on Integra LifeSciences Holdings Corporations Q3 2018 Earnings (IART)Northcoast Research Weighs in on Integra LifeSciences Holdings Corporation's Q3 2018 Earnings (IART)
www.americanbankingnews.com - October 31 at 2:02 PM
Integra LifeSciences Holdings Corporation (IART) to Post FY2019 Earnings of $2.59 Per Share, Oppenheimer Holdings ForecastsIntegra LifeSciences Holdings Corporation (IART) to Post FY2019 Earnings of $2.59 Per Share, Oppenheimer Holdings Forecasts
www.americanbankingnews.com - October 30 at 11:52 AM
Wells Fargo & Company Downgrades Integra LifeSciences Holdings Corporation (IART) to Market PerformWells Fargo & Company Downgrades Integra LifeSciences Holdings Corporation (IART) to Market Perform
www.americanbankingnews.com - October 30 at 12:46 AM

SEC Filings

Integra Lifesciences (NASDAQ:IART) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Integra Lifesciences (NASDAQ:IART) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Integra Lifesciences (NASDAQ IART) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.